A device the size of a multivitamin, clipped onto the vagus nerve in the neck, is showing it can do something anti-inflammatory drugs have done for two decades, only without the injections. SetPoint Medical, the company built around research out of Kevin Tracey’s lab at the Feinstein Institutes for Medical Research, has been running patients with rheumatoid arthritis through trials of an implanted stimulator, and the pattern holding across those trials is consistent: dial in a short burst of electrical current to the vagus nerve once a day, and markers of systemic inflammation go down along with the joint pain and swelling that define the disease.
This matters because rheumatoid arthritis is not a niche problem and its current treatments are not cheap or simple. The disease affects around 1.3 million adults in the United States, and the drugs that actually control it, the anti-TNF biologics like adalimumab and etanercept, and the newer JAK inhibitors, work by suppressing immune signaling chemically, system-wide, for as long as a patient keeps taking them. Some patients stop responding. Some can’t tolerate the side effects. Some simply can’t afford a drug that lists for tens of thousands of dollars a year even before insurance negotiates it down. An implant that produces a similar anti-inflammatory effect through electricity rather than chemistry isn’t just a cute proof of concept. If it works reliably, it’s a genuinely different way to manage a disease that drug companies have been treating the same way since Humira came to market in 2002.
The nerve that tells your immune system to calm down
The science behind this goes back to a discovery Tracey’s team made at the Feinstein Institutes in the late 1990s, while studying sepsis in rats. Cutting the vagus nerve made inflammation worse. Stimulating it suppressed the production of TNF-alpha, the same signaling molecule that anti-TNF drugs are designed to block. The circuit works roughly like this: the vagus nerve, which runs from the brainstem down through the neck and into the chest and abdomen, releases acetylcholine near the spleen. That acetylcholine binds to a receptor called alpha7 nicotinic acetylcholine receptor on macrophages, the immune cells that pump out inflammatory cytokines, and tells them to stand down. Tracey named this the inflammatory reflex, and it reframed the vagus nerve as something closer to a volume knob the brain uses to keep the immune system from overreacting.
Stimulate the vagus, dial down the inflammation. Cut the vagus, lose the brake.
SetPoint Medical’s device, called a microregulator, is built to exploit exactly that circuit. It’s implanted during an outpatient procedure, cuffed around the cervical vagus nerve, and programmed to deliver a brief stimulation, about a minute, once a day. There’s no continuous current, no battery drain from constant operation, and no drug circulating through the bloodstream. The pitch is specificity: instead of suppressing immune function broadly the way a biologic does, the implant is trying to restore a regulatory signal the body already uses on its own.
What the actual trial data says, and what it doesn’t
The first human evidence came out of a small pilot study led by rheumatologist Frieda Koopman at the Academic Medical Center in Amsterdam, published in the Proceedings of the National Academy of Sciences in 2016. Seventeen patients with rheumatoid arthritis who had failed at least one biologic drug had the device implanted. Stimulating the nerve suppressed TNF production in their blood and, in a meaningful share of patients, reduced disease activity scores enough to count as clinical improvement. It was a small, open-label study, the kind of result that gets you funding for a bigger trial rather than a headline on its own, but it was the first time anyone had shown the inflammatory reflex could be turned into a usable treatment in people rather than rodents.
SetPoint followed that pilot with a larger, randomized, sham-controlled pivotal trial called RESET-RA, enrolling patients who had failed or couldn’t tolerate biologic or targeted therapies, the population rheumatologists consider hardest to treat. A sham-controlled design matters here specifically because RA patients can show real symptom improvement from a surgical procedure and the attention of a clinical trial alone, so the only way to know if the current itself is doing anything is to implant a device in every patient and only turn it on in half. SetPoint reported that the trial met its primary endpoint, with patients receiving active stimulation showing significantly better responses on standard RA disease activity measures than those with the device turned off. That’s a meaningfully different kind of evidence than the 2016 pilot, because it controls for the placebo effect of simply having surgery, which in musculoskeletal disease is not trivial.
Specificity comes from anatomy, not chemistry.
Here’s the honest limitation: a sham-controlled pivotal trial meeting its primary endpoint is not the same thing as a drug-beating result. SetPoint hasn’t published data showing its implant outperforms a biologic head to head, and it likely never will run that trial, because sham-controlled device trials and active-comparator drug trials answer different questions. What the current evidence supports is that vagus nerve stimulation does something real and attributable to the stimulation itself, in a population that had already run out of good drug options. Whether that effect is strong enough, and durable enough, to compete with a biosimilar version of adalimumab that now costs a fraction of what Humira did in 2015, is a question the trial wasn’t designed to answer and the market will end up answering instead.
Surgery once versus injections forever
The comparison that matters to a patient isn’t efficacy on a chart, it’s what the treatment actually asks of your life. A biologic means a self-injection or infusion on a recurring schedule, indefinitely, with the drug’s cost and side effect profile following you the whole time. An implant means one outpatient surgical procedure, a recovery period, and then a device running quietly in the background that a clinician can reprogram without open surgery again. For patients who’ve cycled through two or three biologics already and are tired of needles and insurance appeals, that tradeoff is genuinely attractive even if the day-to-day anti-inflammatory effect turns out to be roughly comparable.
| Approach | Mechanism | Administration | Status in RA |
|---|---|---|---|
| Anti-TNF biologics (adalimumab, etanercept) | Antibody binds and neutralizes TNF-alpha circulating in blood | Self-injection or infusion, ongoing | FDA approved, standard of care since early 2000s |
| JAK inhibitors (tofacitinib and similar) | Blocks intracellular signaling that drives cytokine production | Daily oral pill | FDA approved, carries boxed warning for cardiovascular and clotting risk |
| SetPoint Medical vagus nerve implant | Electrical stimulation activates the cholinergic anti-inflammatory pathway | One-time surgical implant, daily automated stimulation | Pivotal trial (RESET-RA) reported positive results; not yet FDA approved |
SetPoint isn’t the only company betting on this
The inflammatory reflex has attracted bigger players than one startup. Galvani Bioelectronics, the joint venture GlaxoSmithKline formed with Verily in 2016 specifically to commercialize bioelectronic treatments for chronic inflammatory disease, is led by Paul-Peter Tak, a rheumatologist who ran some of the earliest clinical work on vagus nerve stimulation in RA before moving into pharmaceutical R&D leadership. That a major pharmaceutical company built a dedicated subsidiary around this mechanism, rather than just licensing a device, tells you the industry takes the biology seriously even if the commercial path is still unproven. GSK’s own research dollars moving into this space is a stronger signal than any single trial result, because pharmaceutical companies tend to fund mechanisms they think will eventually threaten or replace their own drug franchises.
SetPoint’s device also carries FDA Breakthrough Device Designation, a status that speeds up regulatory review for technologies addressing unmet medical need but does not guarantee approval. The company still has to take RESET-RA’s full dataset through FDA review, and even a favorable decision would only be the starting point. Rheumatologists will want to see how the effect holds up at two years and five years, not just across a trial’s primary endpoint window, and insurers will want evidence that paying for a surgical implant up front actually saves money compared to a lifetime of biologic prescriptions before they agree to cover it widely.
Where this actually lands
The realistic outcome isn’t that vagus nerve stimulation replaces anti-TNF drugs. It’s that it becomes an option for the patients biologics have already failed, a population rheumatologists currently manage by cycling through drug after drug and hoping one sticks. If RESET-RA’s result holds up through FDA review and into real-world use, the vagus nerve implant becomes the next rung on that ladder rather than a wholesale replacement for the first rung. The more interesting long-term question is what happens if a device like this works in rheumatoid arthritis and the same cholinergic pathway turns out to control inflammation in Crohn’s disease, lupus, or other conditions driven by the same misbehaving macrophages. That’s the bet Galvani and SetPoint are both actually making, and rheumatoid arthritis is just the first disease simple enough, and well enough understood, to prove it in people.
Credit: Federico Lancellotti on Unsplash